Table 4.
Proportions of participants reporting specific adverse events by intervention group.
Characteristics | Regimen started | |||
---|---|---|---|---|
BAM/ETE | CAS/IMD | p-value* | Total | |
N= 237 | N= 196 | N= 433 | ||
Adverse events, n(%) | 0.064 | |||
Mild | 8 (3.4%) | 15 (7.7%) | 23 (5.3%) | |
Moderate | 0 (0.0%) | 7 (3.6%) | 7 (1.6%) | |
Severe | 1 (0.4%) | 0 (0.0%) | 1 (0.2%) | |
Drug related | 6 (2.5%) | 19 (9.7%) | 0.001 | 25 (5.8%) |
Individual events, n(%) | ||||
Arthomyalgia | 1 (0.4%) | 2 (1.0%) | 0.455 | 3 (0.7%) |
Asthenia | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Chills | 0 (0.0%) | 3 (1.5%) | 0.056 | 3 (0.7%) |
Diarrhea | 1 (0.4%) | 1 (0.5%) | 0.893 | 2 (0.5%) |
Fever | 4 (1.7%) | 17 (8.7%) | <.001 | 21 (4.8%) |
Nausea | 0 (0.0%) | 4 (2.0%) | 0.027 | 4 (0.9%) |
Sight decrease | 0 (0.0%) | 1 (0.5%) | 0.271 | 1 (0.2%) |
Headache | 0 (0.0%) | 1 (0.5%) | 0.271 | 1 (0.2%) |
Dyspnea | 1 (11.1%) | 1 (4.5%) | 0.506 | 2 (6.5%) |
Abdominal pain | 1 (11.1%) | 0 (0.0%) | 0.118 | 1 (3.2%) |
Hematoma | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Paraesthesia | 1 (0.4%) | 0 (0.0%) | 0.363 | 1 (0.2%) |
Itch | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Skin rash | 0 (0.0%) | 2 (1.0%) | 0.119 | 2 (0.5%) |
Dizziness | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Vomit | 0 (0.0%) | 1 (0.5%) | 0.271 | 1 (0.2%) |
*Chi-square or Mann-Whitney test as appropriate.
BAM/ETE, bamlanivimab/etesevimab; CAS/IMD, casirivimab/imdevimab; IQR, interquartile range; BMI, body mass index; SpO2, peripheral oxygen saturation.